UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains

BMC biology, 2023-02, Vol.21 (1), p.21-21, Article 21

2023

Volltextzugriff (PDF)

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations

Cancers, 2022-04, Vol.14 (9), p.2147

2022

Volltextzugriff (PDF)

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)

Cancers, 2023-10, Vol.15 (21), p.5157

2023

Volltextzugriff (PDF)

18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?

BMC medical imaging, 2022-04, Vol.22 (1), p.63-63, Article 63

2022

Volltextzugriff (PDF)

Biochemical and biophysical characterisation of immunoglobulin free light chains derived from an initially unbiased population of patients with light chain disease

PeerJ (San Francisco, CA), 2020-03, Vol.8, p.e8771-e8771, Article e8771

2020

Volltextzugriff (PDF)

Bidirectional conversion of intestinal epithelial cells: NFκB is key

Cancer biology & therapy, 2014-02, Vol.15 (2), p.170-171

Boquoi, Amelie

2014

Volltextzugriff (PDF)

Adenomatous Polyposis Coli mutations in colon cancer: Slipping off the brake and onto the gas pedal

Cancer biology & therapy, 2008-04, Vol.7 (4), p.485-487

2008

Volltextzugriff (PDF)

Multiples Myelom: Diagnostik, Therapie und neue Entwicklungen

Der Klinikarzt, 2018-09, Vol.47 (9), p.418-425

2018

Volltextzugriff (PDF)

De Novo Sequencing of Antibody Light Chain Proteoforms from Patients with Multiple Myeloma

Analytical chemistry (Washington), 2021-08, Vol.93 (30), p.10627-10634

2021

Volltextzugriff (PDF)

Ubiquitination of Myc: Flipping the switch

Cancer biology & therapy, 2006-08, Vol.5 (8), p.907-908

2006

Volltextzugriff (PDF)

Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma

Journal of Blood Disorders, 2023-12, Vol.10 (3)

Boquoi, Amelie

2023

Volltextzugriff (PDF)

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma

Drug delivery and translational research, 2023-04, Vol.13 (4), p.915-923

2023

Volltextzugriff (PDF)

Therapy-Related Myeloid Neoplasms Following Treatment for Multiple Myeloma : A Single-Center Analysis

Blood, 2019-11, Vol.134 (Supplement_1), p.4261-4261

2019

Volltextzugriff (PDF)

Neut-X can be successfully used as diagnostic and prognostic tool in MDS

Leukemia research, 2019-11, Vol.86, p.106224-106224, Article 106224

2019

Volltextzugriff (PDF)

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Clinical cancer research, 2020-11, Vol.26 (22), p.5879-5886

2020

Volltextzugriff (PDF)

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Blood, 2018-11, Vol.132 (Supplement 1), p.2003-2003

2018

Volltextzugriff (PDF)

Maintenance therapy (MT) with 25 versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant-eligible patients (pts) with multiple myeloma (MM)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.8016-8016

2018

Volltextzugriff (PDF)

p16Ink4a inhibits histologic progression and angiogenic signaling in min colon tumors

Cancer biology & therapy, 2005-12, Vol.4 (12), p.1389-1394

2005

Volltextzugriff (PDF)

Reversible cell cycle inhibition and premature aging features imposed by conditional expression of p16 Ink4a

Aging cell, 2015-02, Vol.14 (1), p.139-147

2015

Volltextzugriff (PDF)

Reversible cell cycle inhibition and premature aging features imposed by conditional expression of p16Ink4a

Aging cell, 2015-02, Vol.14 (1), p.139-147

2015

Volltextzugriff (PDF)

Favourable Outcome of Elderly Patients with Multiple Myeloma Treated with Tandem Melphalan 100 High-Dose Therapy, Autologous Stem Cell Transplantation and Novel Agents - a Single Center Experience

Blood, 2016-12, Vol.128 (22), p.3460-3460

2016

Volltextzugriff (PDF)

Abstract 2975: Widespread cell cycle inhibition and features of premature aging in mice with conditional expression of p16Ink4a

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2975-2975

2011

Volltextzugriff (PDF)

Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis

International journal of cancer, 2016-11, Vol.139 (10), p.2343-2352

2016

Volltextzugriff (PDF)

Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032

Cancer prevention research (Philadelphia, Pa.), 2009-09, Vol.2 (9), p.800-806

2009

Volltextzugriff (PDF)

Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor

Cancer research (Chicago, Ill.), 2003-08, Vol.63 (16), p.5105-5113

2003

Volltextzugriff (PDF)

1 – 25 von 31

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(29)

Publikationsform

Artikel
(31)

Sprache

Englisch
(30)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Widespread amyloidogenicity potential of multiple myeloma patient-derived immunoglobulin light chains

Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)

18F-FDG-PET/CT in relapsed multiple myeloma: Are prognostic thresholds different from first-line therapy?

Biochemical and biophysical characterisation of immunoglobulin free light chains derived from an initially unbiased population of patients with light chain disease

Bidirectional conversion of intestinal epithelial cells: NFκB is key

Adenomatous Polyposis Coli mutations in colon cancer: Slipping off the brake and onto the gas pedal

Multiples Myelom: Diagnostik, Therapie und neue Entwicklungen

De Novo Sequencing of Antibody Light Chain Proteoforms from Patients with Multiple Myeloma

Ubiquitination of Myc: Flipping the switch

Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma

Therapy-Related Myeloid Neoplasms Following Treatment for Multiple Myeloma : A Single-Center Analysis

Neut-X can be successfully used as diagnostic and prognostic tool in MDS

Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Maintenance therapy (MT) with 25 versus 5 mg lenalidomide (Len) after prolonged Len consolidation therapy (CT) in newly-diagnosed, transplant-eligible patients (pts) with multiple myeloma (MM)

p16Ink4a inhibits histologic progression and angiogenic signaling in min colon tumors

Reversible cell cycle inhibition and premature aging features imposed by conditional expression of p16 Ink4a

Reversible cell cycle inhibition and premature aging features imposed by conditional expression of p16Ink4a

Favourable Outcome of Elderly Patients with Multiple Myeloma Treated with Tandem Melphalan 100 High-Dose Therapy, Autologous Stem Cell Transplantation and Novel Agents - a Single Center Experience

Abstract 2975: Widespread cell cycle inhibition and features of premature aging in mice with conditional expression of p16Ink4a

Lenalidomide consolidation treatment in patients with multiple myeloma suppresses myelopoieses but spares erythropoiesis

Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032

Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor

Suchergebnisse filtern